Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (7826)	4/5/2000 9:35:00 AM
From: lrb	Respond to of 9719

Thanks, PB, for your reply and for the links. Here is a link to an InterMune PR in which Dr. King, the author of the critical commentary you cited, says "Based on the reviews conducted by my colleagues, I am more confident that these patients suffered from idiopathic pulmonary fibrosis and that the results of this study indicate that interferon gamma-1b is a promising agent for the treatment of idiopathic pulmonary fibrosis." biz.yahoo.com Since Dr. King is a medical advisor to InterMune, I am a little confused by this exchange. I don't understand why he would write the original letter before the completion of the reviews conducted by his colleagues.